Sustained sympathetic and blood pressure reduction 1 year after renal denervation in patients with resistant hypertension

Hypertension

Volumn 64, Issue 1, 2014, Pages 118-124

  Hering, Dagmara ^a,b   Marusic, Petra ^a   Walton, Antony S ^c   Lambert, Elisabeth A ^a,d   Krum, Henry ^c,e   Narkiewicz, Krzysztof ^b   Lambert, Gavin W ^a,d   Esler, Murray D ^a,c   Schlaich, Markus P ^a,c,d  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c ALFRED HOSPITAL   (Australia)

^d Department of Biomedical Science   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

hypertension resistant to conventional therapy; sympathetic nervous system

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; METOPROLOL; MOXONIDINE; PRAZOSIN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

ADRENERGIC SYSTEM; ADULT; AMBULATORY MONITORING; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITOR; BLOOD PRESSURE MONITORING; CATHETER; CLINICAL ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY DENERVATION; MALE; MUSCLE SYMPATHETIC NERVE ACTIVITY; NEUROGRAPHY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RADIOFREQUENCY ABLATION DEVICE; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

HYPERTENSION RESISTANT TO CONVENTIONAL THERAPY; SYMPATHETIC NERVOUS SYSTEM;

ADULT; AGED; BLOOD PRESSURE; CROSS-OVER STUDIES; DENERVATION; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 84902547843     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.03098     Document Type: Article

References (34)

1. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood- pressure-related disease, 2001. Lancet. 2008;371: 1513-1518.
2. Go AS, Mozaffarian D, Roger VL, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127: 143-152.
3. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51: 1403-1419.
4. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, O'Connor PJ, Selby JV, Ho PM. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125: 1635-1642.
5. Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, Cataliotti A, Malatino LS; CREED Investigators. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension. 2002;40: 41-46.
6. Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM, Caldarella MP, Neri M, Cuccurullo F, Mezzetti A. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18: 1422-1428.
7. Mancia G, De Backer G, Dominiczak A, et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25: 1105-1187.
8. Zhang Y, Zhang X, Liu L, Zanchetti A; FEVER Study Group. Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J. 2011;32: 1500-1508.
9. Tsioufis C, Kordalis A, Flessas D, Anastasopoulos I, Tsiachris D, Papademetriou V, Stefanadis C. Pathophysiology of resistant hypertension: the role of sympathetic nervous system. Int J Hypertens. 2011;2011:642416.
10. Esler M, Jennings G, Biviano B, Lambert G, Hasking G. Mechanism of elevated plasma noradrenaline in the course of essential hypertension. J Cardiovasc Pharmacol. 1986;8(suppl 5):S39-S43. (Pubitemid 16039090)
11. Esler M, Lambert G, Jennings G. Regional norepinephrine turnover in human hypertension. Clin Exp Hypertens A. 1989;11(suppl 1): 75-89.
12. Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, Hastings J, Aggarwal A, Esler MD. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension. 2004;43: 169-175.
13. Hering D, Kara T, Kucharska W, Somers VK, Narkiewicz K. High-normal blood pressure is associated with increased resting sympathetic activity but normal responses to stress tests. Blood Press. 2013;22: 183-187.
14. Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, Esler MD, Schlaich MP. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013;61: 457-464.
15. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter- based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373: 1275-1281.
16. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic- nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361: 932-934.
17. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J. 2012;33: 1058-1066.
18. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376: 1903-1909.
19. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57: 911-917.
20. Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA; Symplicity HTN-2 Investigators. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126: 2976-2982.
21. Symplicity™ RDN System Clinical Trial Data. http:// www.medtronicrdn. com/intl/healthcare-professionals/symplicity-rdn-system/ symplicity-clinical- trial-data/index.htm. Accessed July 5, 2013.
22. Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, Haller H, Sweep FC, Diedrich A, Jordan J, Tank J. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficultto- control hypertensive patients: prospective case series. Hypertension. 2012;60: 1485-1490.
23. Hansen JM, Abildgaard U, Fogh-Andersen N, Kanstrup IL, Bratholm P, Plum I, Strandgaard S. The transplanted human kidney does not achieve functional reinnervation. Clin Sci (Lond). 1994;87: 13-20.
24. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130: 461-470.
25. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, Sobotka PA, Böhm M, Cremers B, Esler MD, Schlaich MP. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23: 1250-1257.
26. Narkiewicz K, Phillips BG, Kato M, Hering D, Bieniaszewski L, Somers VK. Gender-selective interaction between aging, blood pressure, and sympathetic nerve activity. Hypertension. 2005;45: 522-525.
27. Mahfoud F, Ukena C, Schmieder RE, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128: 132-140.
28. Wallin BG, Thompson JM, Jennings GL, Esler MD. Renal noradrenaline spillover correlates with muscle sympathetic activity in humans. J Physiol. 1996;491(Pt 3): 881-887.
29. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Böhm M, Hoppe UC. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59: 901-909.
30. Brandt MC, Reda S, Mahfoud F, Lenski M, Böhm M, Hoppe UC. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Am Coll Cardiol. 2012;60: 1956-1965.
31. Hering D, Lambert EA, Marusic P, Ika-Sari C, Walton AS, Krum H, Sobotka PA, Mahfoud F, Böhm M, Lambert GW, Esler MD, Schlaich MP. Renal nerve ablation reduces augmentation index in patients with resistant hypertension. J Hypertens. 2013;31: 1893-1900.
32. Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffiths R, Kumar AP, Kim HS, Smithies O, Le TH, Coffman TM. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A. 2006;103: 17985-17990.
33. Mancia G, Dell'Oro R, Quarti-Trevano F, Scopelliti F, Grassi G. Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease. J Hypertens Suppl. 2006;24:S51-S56. (Pubitemid 44336824)
34. Wang L, Lu CZ, Zhang X, Luo D, Zhao B, Yu X, Xia DS, Chen X, Zhao XD. The effect of catheter based renal synthetic denervation on renin- angiotensin-aldosterone system in patients with resistant hypertension. Zhonghua Xin Xue Guan Bing Za Zhi. 2013;41: 3-7.